# TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study

Study · id `cardio:ct-nct04570228` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04570228](<https://clinicaltrials.gov/study/NCT04570228>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04570228

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 205 participants.

## Technical summary

Registry record NCT04570228. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-01 (anticipated); primary completion 2023-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 205 participants (planned count; ClinicalTrials.gov record NCT04570228, source copy `cardio:ctgov-nct04570228-2022-04-01`, retrieved 2026-10-31)
- Planned start: 2023-01-01 (anticipated) (ClinicalTrials.gov record NCT04570228, source copy `cardio:ctgov-nct04570228-2022-04-01`, retrieved 2026-10-31)
- Primary completion: 2023-12-01 (anticipated) (ClinicalTrials.gov record NCT04570228, source copy `cardio:ctgov-nct04570228-2022-04-01`, retrieved 2026-10-31)
- Completion: 2025-12-01 (anticipated) (ClinicalTrials.gov record NCT04570228, source copy `cardio:ctgov-nct04570228-2022-04-01`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04570228-2022-04-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study
- Condition: Pulmonary Arterial Hypertension
- Intervention (Device): Pulmonary artery denervation
- Intervention (Device): Sham procedure
- Lead sponsor: SoniVie Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 686be71d9659ecab6ca7021a5133db91e3eb5a9d463b7df108f12b981083f1a9
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
